Literature DB >> 11604031

Is there a difference between leads and drugs? A historical perspective.

T I Oprea1, A M Davis, S J Teague, P D Leeson.   

Abstract

To be considered for further development, lead structures should display the following properties: (1) simple chemical features, amenable for chemistry optimization; (2) membership to an established SAR series; (3) favorable patent situation; and (4) good absorption, distribution, metabolism, and excretion (ADME) properties. There are two distinct categories of leads: those that lack any therapeutic use (i.e., "pure" leads), and those that are marketed drugs themselves but have been altered to yield novel drugs. We have previously analyzed the design of leadlike combinatorial libraries starting from 18 lead and drug pairs of structures (S. J. Teague et al. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748). Here, we report results based on an extended dataset of 96 lead-drug pairs, of which 62 are lead structures that are not marketed as drugs, and 75 are drugs that are not presumably used as leads. We examined the following properties: MW (molecular weight), CMR (the calculated molecular refractivity), RNG (the number of rings), RTB (the number of rotatable bonds), the number of hydrogen bond donors (HDO) and acceptors (HAC), the calculated logarithm of the n-octanol/water partition (CLogP), the calculated logarithm of the distribution coefficient at pH 7.4 (LogD(74)), the Daylight-fingerprint druglike score (DFPS), and the property and pharmacophore features score (PPFS). The following differences were observed between the medians of drugs and leads: DeltaMW = 69; DeltaCMR = 1.8; DeltaRNG = DeltaHAC =1; DeltaRTB = 2; DeltaCLogP = 0.43; DeltaLogD(74) = 0.97; DeltaHDO = 0; DeltaDFPS = 0.15; DeltaPPFS = 0.12. Lead structures exhibit, on the average, less molecular complexity (less MW, less number of rings and rotatable bonds), are less hydrophobic (lower CLogP and LogD(74)), and less druglike (lower druglike scores). These findings indicate that the process of optimizing a lead into a drug results in more complex structures. This information should be used in the design of novel combinatorial libraries that are aimed at lead discovery.

Mesh:

Substances:

Year:  2001        PMID: 11604031     DOI: 10.1021/ci010366a

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  120 in total

Review 1.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

2.  Filtering databases and chemical libraries.

Authors:  Paul S Charifson; W Patrick Walters
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

3.  Reactant- and product-based approaches to the design of combinatorial libraries.

Authors:  Valerie J Gillet
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

4.  Current trends in lead discovery: are we looking for the appropriate properties?

Authors:  Tudor I Oprea
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

Review 5.  Global analysis of large-scale chemical and biological experiments.

Authors:  David E Root; Brian P Kelley; Brent R Stockwell
Journal:  Curr Opin Drug Discov Devel       Date:  2002-05

Review 6.  Reactant- and product-based approaches to the design of combinatorial libraries.

Authors:  Valerie J Gillet
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

Review 7.  Filtering databases and chemical libraries.

Authors:  Paul S Charifson; W Patrick Walters
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

Review 8.  Current trends in lead discovery: are we looking for the appropriate properties?

Authors:  Tudor I Oprea
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

Review 9.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

10.  Expansion of the structure-activity relationships of BACE1 inhibitors by harnessing diverse building blocks prepared using a unified synthetic approach.

Authors:  Joan Mayol-Llinàs; Shiao Chow; Adam Nelson
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.